Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GKT137831 in Primary Biliary Cholangitis with Elevated Alkaline Phosphatase
DRKS00013664Phase 2Recruiting
- Sponsor
- Genkyotex
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of setanaxib in primary biliary cholangitis (PBC) (3 arms), sponsored by Genkyotex. Primary endpoints: Efficacy: change in alkaline phosphatase and Safety and tolerability of GKT137831. Started Dec 2017; status: recruiting.
02
Drugs
setanaxib
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on DRKS00013664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00013664.